STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Clinical trials for STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major cancer trial tests gentler chemo schedule
Disease control TerminatedThis study aims to find out if giving a common chemotherapy drug (cisplatin) weekly alongside radiation is easier for patients to tolerate than giving it every three weeks. It will also check if the weekly schedule is at least as good at helping patients live longer. The trial in…
Matched conditions: STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New Two-Drug attack on tough head and neck cancers
Disease control OngoingThis study is testing if adding a new drug called ipatasertib to a standard immunotherapy (pembrolizumab) works better for controlling advanced head and neck cancer that has returned or spread. It will involve about 52 adults who have not yet received treatment for their advanced…
Matched conditions: STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Radiation boost tested to help immune system fight advanced head and neck cancer
Disease control OngoingThis study is for adults whose head and neck cancer has spread to a few other places in the body. It tests if adding a targeted course of radiation therapy to standard immunotherapy helps patients live longer than immunotherapy alone. About 290 participants will be randomly assig…
Matched conditions: STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
New hope for tough head & neck cancers that resist First-Line treatment
Disease control OngoingThis study is for people with advanced head and neck cancer that has returned or spread after their first immunotherapy treatment stopped working. It compares three different drug combinations to see which one is better at controlling the cancer and helping patients live longer. …
Matched conditions: STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC